New Century Rating: Follow Huahai Pharmaceutical Company and related personnel receiving a warning letter from the Zhejiang Securities Regulatory Bureau
Huahai Pharmaceutical (600521): Leading pharmaceutical manufacturing enterprises go overseas and welcome growth domestically
Huahai Pharmaceutical (600521): Short-term APIs and domestic formulations are under pressure, optimistic that preparations will go overseas
Huahai Pharmaceutical (600521): The two-wheel drive business for APIs and formulations is progressing steadily
Huahai Pharmaceutical (600521): Steady performance and rapid growth in formulation business
Huahai Pharmaceutical (600521): Performance is in line with expectations to promote the internationalization of formulations
Huahai Pharmaceutical (600521): The advantages of API integration help high performance growth, outstanding R&D innovation highlights
Huahai Pharmaceutical (600521): The 2022 performance is in line with expectations, and the pharmaceutical business is developing rapidly
Huahai Pharmaceutical (600521): Dual wheel drive performance can be expected, increased innovation is expected to open up space
Huahai Pharmaceutical (600521): Signed a VV116 production agreement and operations continued to rise
Huahai Pharmaceutical (600521): Performance is in line with expectations and the inflection point of recovery throughout the year is clear
Huahai Pharmaceutical (600521): Internationalization of advanced pharmaceutical manufacturing leaders opens up room for growth
Huahai Pharmaceutical (600521): the company's performance enters the high growth channel and the growth momentum is expected to be further strengthened in the medium term.
Huahai Pharmaceutical (600521) 2022 Annual report performance Forecast comments: the overall improvement of the three major business sectors led the company's quarterly and semi-annual performance to an all-time high
Huahai Pharmaceutical Co., Ltd. (600521): Yueming Pharmaceutical Advanced Manufacturing Leader set sail again
Huahai Pharmaceutical (600521): Growth momentum is still strong, equity incentives are inspiring
Comments on Huahai Pharmaceutical (600521) Annual report 2020 and Quarterly report 2021: high performance growth Equity incentive demonstrates the Company's confidence
Comments on Huahai Pharmaceutical (600521) 2020 Annual report and 2021 Quarterly report: note the new increment and new momentum of forward integration
Huahai Pharmaceutical Co., Ltd. (600521): short-term fluctuation and medium-term catalysis
Huahai Pharmaceutical (600521): Time and space for leading pharmaceutical exporters to grow
No Data